Cargando…
MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis
The 2016 World Health Organization classification defines diffuse large B-cell lymphoma (DLBCL) subtypes based on Epstein-Barr virus (EBV) infection and oncogenic rearrangements of MYC/BCL2/BCL6 as drivers of lymphomagenesis. A subset of DLBCL, however, is characterized by activating mutations in MY...
Autores principales: | Vermaat, Joost S., Somers, Sebastiaan F., de Wreede, Liesbeth C., Kraan, Willem, de Groen, Ruben A.L., Schrader, Anne M. R., Kerver, Emile D., Scheepstra, Cornelis G., Berenschot, Henriëtte, Deenik, Wendy, Wegman, Jurgen, Broers, Rianne, de Boer, Jan-Paul D., Nijland, Marcel, van Wezel, Tom, Veelken, Hendrik, Spaargaren, Marcel, Cleven, Arjen H., Kersten, Marie José, Pals, Steven T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012469/ https://www.ncbi.nlm.nih.gov/pubmed/31123031 http://dx.doi.org/10.3324/haematol.2018.214122 |
Ejemplares similares
-
MYD88 in the driver’s seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications
por: de Groen, Ruben A.L., et al.
Publicado: (2019) -
High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites
por: Kraan, W, et al.
Publicado: (2013) -
Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations
por: Kersten, M J, et al.
Publicado: (2014) -
The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain
por: Minderman, Marthe, et al.
Publicado: (2023) -
Correction to: The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma
por: Ren, Zemin, et al.
Publicado: (2021)